JPH203 (KYT-0353) (Synonyms: KYT-0353) |
Catalog No.GC32690 |
JPH203 (KYT-0353), a selective L-type amino acid transporter 1 inhibitor, significantly inhibited leucine uptake and cell growth in HT-29 YD-38 and leukemia cells, with IC50 values of 0.06 μM and 4.1 μM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1037592-40-7
Sample solution is provided at 25 µL, 10mM.
JPH203 (KYT-0353), a selective L-type amino acid transporter 1 inhibitor, significantly inhibited leucine uptake and cell growth in HT-29 YD-38 and leukemia cells, with IC50 values of 0.06 μM and 4.1 μM, respectively[1,5].
JPH203 (KYT-0353) can up-regulate the activated forms of pro-apoptotic factors such as Bad, Bax, Bak and caspase-9 and down-regulate anti-apoptotic factors such as Bcl-2,Bcl-xl, activation of mitochondria dependent apoptotic signaling pathway JPH203 (KYT-0353), can distinguish the relative abundance of LAT1 and LAT2, and it has high selectivity for LAT1[2]. JPH203 (KYT-0353) is metabolically stable in liver microsomes of mice, rats, dogs, monkeys and humans[3]. JPH203 (KYT-0353) induced both G2/M and G0/G1 cell cycle arrest, as well as reduced the S phase accompanied by altered expression of the proteins in cell cycle progression: cyclin D1, CDK4, and CDK6[4]. Study on leukemia reported that JPH203 (KYT-0353) induced type ІІ cell death, autophagy, followed by caspase-3-dependent apoptosis at 48 h after treatment[6].LAT1 inhibition by JPH203 (KYT-0353) sensitizes cancer cells to radiation by enhancing cellular senescence via mTOR downregulation[7].
In vivo model, using intravenously administered JPH203 (KYT-0353) (12.5 and 25.0 mg/kg), a statistically significant inhibition of growth of HT-29 tumors transplanted to nude mice with only a slight decrease in body weight[4].
References:
[1]: Yun DW, Lee SA, et,al. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. J Pharmacol Sci. 2014;124(2):208-17. doi: 10.1254/jphs.13154fp. Epub 2014 Feb 4. PMID: 24492461.
[2]: Choi DW, Kim DK, et,al. JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells. Korean J Physiol Pharmacol. 2017 Nov;21(6):599-607. doi: 10.4196/kjpp.2017.21.6.599. Epub 2017 Oct 30. PMID: 29200902; PMCID: PMC5709476.
[3]: Wempe MF, Rice PJ, et,al. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet. 2012;27(1):155-61. doi: 10.2133/dmpk.dmpk-11-rg-091. Epub 2011 Sep 13. PMID: 21914964.
[4]: Yothaisong S, Dokduang H, et,al. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol. 2017 Mar;39(3):1010428317694545. doi: 10.1177/1010428317694545. PMID: 28347255.
[5]: Oda K, Hosoda N, et,al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010 Jan;101(1):173-9. doi: 10.1111/j.1349-7006.2009.01386.x. Epub 2009 Oct 8. PMID: 19900191.
[6]: Rosilio, C, Nebout, M,et al. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia 29, 1253–1266 (2015). https://doi.org/10.1038/leu.2014.338
[7]: Bo T, Kobayashi S, et,al. LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence. Transl Oncol. 2021 Nov;14(11):101212. doi: 10.1016/j.tranon.2021.101212. Epub 2021 Aug 27. PMID: 34461558; PMCID: PMC8405945.
Average Rating: 5
(Based on Reviews and 20 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *